MAJI (Exousia Pro) EBITDA Margin %: 0.00% (As of Jan. 2021)

What is Exousia Pro EBITDA Margin %?

Exousia Pro MAJI +5.90% EBITDA Margin % is 0.00% as of Jan. 2021.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Exousia Pro's EBITDA for the three months ended in Jan. 2021 was $-0.13 Mil. Exousia Pro's Revenue for the three months ended in Jan. 2021 was $0.00 Mil. Therefore, Exousia Pro's EBITDA margin for the quarter that ended in Jan. 2021 was 0.00%.

Exousia Pro (OTCPK:MAJI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Exousia Pro EBITDA Margin % Related Terms

Exousia Pro EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Exousia Pro's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro EBITDA Margin % Chart

Exousia Pro Annual Data

Trend

Apr11

Apr12

Apr18

Apr19

EBITDA Margin %

0.00

Exousia Pro Quarterly Data
	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MAJI vs HCCH, GRNV, AGBA: EBITDA Margin % Comparison

For the Biotechnology subindustry, Exousia Pro's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exousia Pro EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exousia Pro's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Exousia Pro's EBITDA Margin % falls into.

Save Embed

Exousia Pro EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Exousia Pro's EBITDA Margin % for the fiscal year that ended in Apr. 2019 is calculated as

EBITDA Margin %	=	EBITDA (A: Apr. 2019 )	/	Revenue (A: Apr. 2019 )
	=	-0.125	/	0
	=	%

Exousia Pro's EBITDA Margin % for the quarter that ended in Jan. 2021 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jan. 2021 )	/	Revenue (Q: Jan. 2021 )
	=	-0.134	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Exousia Pro (MAJI) has a EBITDA Margin % of 0.00% as of Jan. 2021. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Exousia Pro and its competitors.

Is Exousia Pro's EBITDA Margin % too high?

Exousia Pro's current EBITDA Margin % is 0.00%.

How does Exousia Pro's EBITDA Margin % compare to HCCH and GRNV?

Exousia Pro's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Exousia Pro and its competitors. Exousia Pro's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Exousia Pro stock overvalued right now?

Exousia Pro (MAJI) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Exousia Pro (MAJI), the current EBITDA Margin % is 0.00% as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Industry Healthcare Biotechnology

Comparable Companies HCCH GRNV AGBA LACQ ORSN JFK LOAC TZAC KXIN CPMD CCXX CCX FPAC VTIQ SPAQ FEAC CCH CPAA LSE:EVRA GHIV

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702

Website https://www.nextelmedical.com

Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.